BAXBaxter International
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 176.5 vs a 30.7 median over 30 quarters (+475% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BAX's price assumes
Baxter International did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.14× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.11
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 1.03
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.11
- EV / EBIToperating margin −2.4%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.03
- Market capitalisation517.0 million shares, counted Jul 23, 2026
- $13.1B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Medical Instruments & Supplies
The closest names by size in the same industry